Veradermics, Inc
Veradermics, Inc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Safety and Efficacy of VDPHL01 in Males With AGA on December 15, 2026. There are 2 upcoming events on record.
Cash runway is approximately 116.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | Safety and Efficacy of VDPHL01 in Males With AGA | Trial Milestone | Phase 3 |
| June 15, 2027 | Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | Trial Milestone | Phase 3 |
Track MANE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MANE in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 15, 2026 | Safety and Efficacy of VDPHL01 in Males and Females With AGA | Trial Milestone | Phase 2 |
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 15, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 1, 2026 | 8-K filed: Material agreement | Corporate | — |
| April 27, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| April 27, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 30, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 15, 2026 | Efficacy and Safety of VDPHL01 in Males With AGA | Trial Milestone | Phase 2/Phase 3 |
| February 25, 2025 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.